430 related articles for article (PubMed ID: 27261328)
1. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N; Hazlehurst LA
J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
[TBL] [Abstract][Full Text] [Related]
2. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
4. New Agents in Multiple Myeloma: An Examination of Safety Profiles.
Bringhen S; De Wit E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):391-407.e5. PubMed ID: 28601492
[TBL] [Abstract][Full Text] [Related]
5. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Sonneveld P; De Wit E; Moreau P
Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
7. [Treatment algorithms for multiple myeloma in Japan].
Ozaki S
Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
[TBL] [Abstract][Full Text] [Related]
8. [Novel agents in multiple myeloma treatment].
Ito S
Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
[TBL] [Abstract][Full Text] [Related]
9. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
Lee HC; Mark TM; Shah JJ
Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
[TBL] [Abstract][Full Text] [Related]
10. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
11. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
13. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
14. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
15. New generation drugs for treatment of multiple myeloma.
Alanazi F; Kwa FAA; Burchall G; Jackson DE
Drug Discov Today; 2020 Feb; 25(2):367-379. PubMed ID: 31765717
[TBL] [Abstract][Full Text] [Related]
16. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
17. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
18. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
19. How I treat myeloma with new agents.
Moreau P
Blood; 2017 Sep; 130(13):1507-1513. PubMed ID: 28747306
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
Tokuhira M
Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]